Drugs / STP707
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05309915 | Feb → Aug 2022 | — | Sirnaomics | Completed | No outcome recorded |
| Phase 1 | NCT05037149 | Nov 2021 → Mar 2024 | neoplasm | Sirnaomics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05309915 ↗ |
| Known as | STP707 Powder for Injection | “STP707 Powder for Injection” NCT05037149 ↗ |
| Modality | Small interfering RNA (siRNA) | “STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.” NCT05309915 ↗ |
| Route | Intravenous | “STP707 3 mg dose IV infusion” NCT05037149 ↗ |